Contribution of Nasal IgE Production to the Boost of Systemic Allergen-specific IgE Upon Nasal Allergen Contact

Recruiting N/A Interventional Study
Allergy
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 60
Sex
Any
Study type
Interventional
Purpose
Basic Science
Participants needed
30 (estimated)
Sponsor
Medical University of Vienna · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
IgE-associated allergies are consistently on the rise forming an enormous wellbeing concern and affecting about 25% of the population around the world, with main prevalence in developed nations. Birch pollen is one important allergen driving allergic conjunctivitis and rhinitis. The characteristics and location IgE producing cells in the nose and their contribution to the subsequent increase in al…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Birch pollen sensitized subjects * Moderate to severe allergic rhinitis to birch pollen allergen for at least two seasons according to their medical history * Sensitization to Bet v 1 (Bet v 1 specific IgE: 3.5 kU/L or higher as specified by UniCAP-FEIA) * CD203c or CD63 …
Contacts

Sven Schneider, MD

+4314040034380

sven.schneider@meduniwien.ac.at

CONTACT

Julia Eckl-Dorna, MD, PhD

+4314040034380

julia.eckl-dorna@meduniwien.ac.at

CONTACT